EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastases
Combination therapies show promise for lung cancer with brain spread
This systematic review and network meta-analysis of 5432 patients with EGFR-mutated non-small cell lung cancer and brain metastases found th…
New data suggests that combining specific drugs can improve survival and slow cancer growth in patients with lung cancer that has spread to …
First-line immune checkpoint inhibitors plus anti-angiogenic therapy improve progression-free survival and response rates in advanced RCC
Combination Therapy Shows Better Outcomes for Advanced Renal Cell Carcinoma
This meta-analysis of 4,977 patients found that first-line immune checkpoint inhibitors combined with anti-angiogenic therapy significantly …
A new combination of immune checkpoint inhibitors and anti-angiogenic therapy shows better survival rates than standard treatment for advanc…
Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits
New Treatment Combinations Show Promise for Advanced Lung Cancer
This systematic review and meta-analysis of 3,606 patients evaluated 8 treatment strategies for advanced EGFR-mutant NSCLC. The analysis fou…
Specific drug combinations, including ivonescimab and amivantamab, show potential benefits for patients with advanced EGFR-mutant lung cance…